Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1395937 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $19.48Day +1.35%Mkt cap $1.7B1Y +95.0%Off 52W high −23.9%Vol (1Y) 56.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,614 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest23.5% of sh out |
| Days to cover9.8d |
| 13F net flow (QoQ)−3.29% |
| Top-10 13F concentration45.1% |
| Next report (est.)2026-10-29 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$217.2M |
| Earnings (TTM)-$243.2M |
| ROE−161.8% |
| Net margin−165.6% |
| Debt / equity5.32× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−7.3% |
| 1Y+95.0% |
| 3Y−8.6% |
| 5Y+33.6% |
| 10Y+59.4% |
| Since incept. (ann.)+4.8% |
Total return through 2026-07-30 · series begins 2016-03-03. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)56.8% |
| Ann. volatility (3Y)57.3% |
| Sharpe (1Y)1.40 |
| Sharpe (3Y)0.24 |
| Max drawdown (1Y)−32.6% |
| Max drawdown (3Y)−64.8% |
| Beta (3Y vs SPY)0.49 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 8.3M | $193M | 9.36% | +0.2% |
| Kynam Capital Management, LP | 8.1M | $188M | 9.13% | +0.0% |
| GOLDMAN SACHS GROUP INC | 5.0M | $117M | 5.67% | −12.3% |
| STATE STREET CORP | 4.4M | $103M | 5.02% | −3.6% |
| BANK OF AMERICA CORP /DE/ | 4.2M | $99M | 4.82% | −9.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8M | $89M | 4.33% | new |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.8M | $88M | 4.29% | new |
| Eversept Partners, LP | 2.9M | $67M | 3.27% | −12.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 114.0% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 19,911,327 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-30 | −$0.48 | — | $64.9M | +223.6% |
| 2025-12-31 | 2026-02-26 | — | — | $68.5M | +791.7% |
| 2025-09-30 | 2025-11-03 | −$0.70 | — | $45.9M | +267.0% |
| 2025-06-30 | 2025-08-04 | −$0.83 | — | $38.0M | +984.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-29 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Biopharmaceutical Cancer Therapeutics 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
